Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoOPTIMIZE: Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as Neoadjuvant Strategy for Pancreatic Cancer
NCT04539808Phase 2Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, gemcitabine, paclitaxel in pancreatic cancer (PC), sponsored by OHSU Knight Cancer Institute. Started May 2021; status: active, not recruiting.
02
Drugs
fluorouracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatingemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04539808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539808.